BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 19788674)

  • 1. Irido-cilio-choroidal melanoma in a 5-year-old boy treated by Ru-106 brachytherapy.
    Pe'er J; Averbukh E; Frenkel S
    Clin Exp Ophthalmol; 2009 Sep; 37(7):742-3. PubMed ID: 19788674
    [No Abstract]   [Full Text] [Related]  

  • 2. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
    Razzaq L; Keunen JE; Schalij-Delfos NE; Creutzberg CL; Ketelaars M; de Keizer RJ
    Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays).
    Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD
    Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasound biomicroscopy features of iris and ciliary body melanomas before and after brachytherapy.
    Torres VL; Allemann N; Erwenne CM
    Ophthalmic Surg Lasers Imaging; 2005; 36(2):129-38. PubMed ID: 15792314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruthenium-106 Plaque Brachytherapy in the Primary Management of Ocular Medulloepithelioma.
    Poon DS; Reich E; Smith VM; Kingston J; Reddy MA; Hungerford JL; Sagoo MS
    Ophthalmology; 2015 Sep; 122(9):1949-51. PubMed ID: 25863421
    [No Abstract]   [Full Text] [Related]  

  • 6. Ruthenium-106 brachytherapy for iris and iridociliary melanomas.
    Marinkovic M; Horeweg N; Laman MS; Bleeker JC; Ketelaars M; Peters FP; Luyten GPM; Creutzberg CL
    Br J Ophthalmol; 2018 Aug; 102(8):1154-1159. PubMed ID: 29122824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plaque radiation therapy for malignant melanoma of the iris and ciliary body.
    Finger PT
    Am J Ophthalmol; 2001 Sep; 132(3):328-35. PubMed ID: 11530044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraocular collision tumour: case report and literature review.
    Coupland SE; Dodson A; Liu H; Du MQ; Angi M; Damato BE
    Graefes Arch Clin Exp Ophthalmol; 2013 May; 251(5):1383-8. PubMed ID: 23232651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting local control of choroidal melanomas following ¹⁰⁶Ru plaque brachytherapy.
    Papageorgiou KI; Cohen VM; Bunce C; Kinsella M; Hungerford JL
    Br J Ophthalmol; 2011 Feb; 95(2):166-70. PubMed ID: 20889528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [High-dose 106Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinico-pathologic study].
    Heindl LM; Lotter M; Strnad V; Sauer R; Naumann GO; Knorr HL
    Ophthalmologe; 2007 Feb; 104(2):149-57. PubMed ID: 17123048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plaque radiotherapy for management of ciliary body and choroidal melanoma with extraocular extension.
    Gündüz K; Shields CL; Shields JA; Cater J; Brady L
    Am J Ophthalmol; 2000 Jul; 130(1):97-102. PubMed ID: 11004266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (106)Ruthenium brachytherapy for ciliary recurrence with supraciliary effusion in retinoblastoma.
    Chhablani J; Romanzo A; Balmer A; Pica A; Gaillard MC; Cozza R; Moeckli R; Munier FL
    Ophthalmic Genet; 2010 Dec; 31(4):190-2. PubMed ID: 20809777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruthenium plaque radiation for iris and iridociliary melanomas: development of dry eyes?
    Razzaq L; de Keizer RJ
    Br J Ophthalmol; 2010 Nov; 94(11):1549-50. PubMed ID: 20516146
    [No Abstract]   [Full Text] [Related]  

  • 14. A clinicopathological study of seven globes enucleated after primary radiation therapy for malignant melanoma of the choroid or ciliary body.
    Liszauer AD; Brownstein S; Corriveau C; Deschênes J
    Can J Ophthalmol; 1990 Dec; 25(7):340-4. PubMed ID: 2090338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of 100 melanomas of the choroid and ciliary body treated by application of ruthenium (RU 106 Rh 106)].
    Grange JD; Gerard JP; Ragab M; Quintero P; Delaroche G; Jean-Louis B; Sentenac I; Fontaniere B; Bievelez B
    Bull Soc Ophtalmol Fr; 1989 May; 89(5):679-82. PubMed ID: 2590984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study.
    Pe'er J; Stefani FH; Seregard S; Kivela T; Lommatzsch P; Prause JU; Sobottka B; Damato B; Chowers I
    Br J Ophthalmol; 2001 Oct; 85(10):1208-12. PubMed ID: 11567966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choroidal melanoma suspect. Conservative treatment and evolution. Case report.
    Zemba M; Malciolu RA
    Rom J Ophthalmol; 2016; 60(4):264-269. PubMed ID: 29450360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of ciliary body melanoma with iodine-125 plaque brachytherapy.
    Krema H; Simpson ER; Pavlin CJ; Payne D; Vasquez LM; McGowan H
    Can J Ophthalmol; 2009 Aug; 44(4):395-400. PubMed ID: 19606159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic disease, eye retention and visual function in conservative treatment of uveal melanoma.
    Bornfeld N; Chauvel P; Sauerwein W; Friedrichs W; Tiburtius T; Wessing A; Foerster MH
    Front Radiat Ther Oncol; 1997; 30():97-110. PubMed ID: 9205890
    [No Abstract]   [Full Text] [Related]  

  • 20. Multifocal intraocular malignant melanoma: report of two cases and review of the literature.
    Dithmar S; Völcker HE; Grossniklaus HE
    Ophthalmology; 1999 Jul; 106(7):1345-8. PubMed ID: 10406619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.